All In Biotech

Drug Trial Radar · NCT06585449

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington's Disease

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Oct 14, 2024

Primary completion

Jul 5, 2028

Study completion Jul 5, 2028

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Sep 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.

Conditions

  • Huntington's Disease

Interventions

  • ALN-HTT02Drug

    ALN-HTT02 will be administered intrathecally

  • PlaceboDrug

    Placebo will be administered intrathecally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs) in the Double-blind Part of the StudyTime frame: Up to 12 months
  2. Frequency of AEs in the Open-label Part of the StudyTime frame: Up to 12 months
  3. Frequency of AEs in the OLE Part of the StudyTime frame: Up to 36 months

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Edmonton, Canada · Recruiting

  • Clinical Trial Site

    Montreal, Canada · Recruiting

  • Clinical Trial Site

    Ottawa, Canada · Recruiting

  • Clinical Trial Site

    Vancouver, Canada · Recruiting

  • Clinical Trial Site

    Berlin, Germany · Recruiting

  • Clinical Trial Site

    Bochum, Germany · Recruiting

  • Clinical Trial Site

    Bonn, Germany · Recruiting

  • Clinical Trial Site

    Dresden, Germany · Recruiting

  • Clinical Trial Site

    Münster, Germany · Recruiting

  • Clinical Trial Site

    Taufkirchen, Germany · Recruiting

  • Clinical Trial Site

    Ulm, Germany · Recruiting

  • Clinical Trial Site

    Birmingham, United Kingdom · Recruiting

  • Clinical Trial Site

    Cambridge, United Kingdom · Recruiting

  • Clinical Trial Site

    Cardiff, United Kingdom · Recruiting

  • Clinical Trial Site

    Glasgow, United Kingdom · Recruiting

  • Clinical Trial Site

    Greater Manchester, United Kingdom · Recruiting

  • Clinical Trial Site

    London, United Kingdom · Recruiting

  • Clinical Trial Site

    Oxford, United Kingdom · Recruiting

  • Clinical Trial Site

    Plymouth, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.